We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pharmaceutical stocks have been under pressure since last year on pricing and regulatory concerns and Eli Lily shares have been no different. That said, the stock has done modestly better than the peer group; it is up +5.7% over the last 12 months vs. +1.7% gain for the Zacks Pharma industry and -0.7% decline for the Zacks Medical sector as a whole. Lilly’s recent high-profile pipeline setbacks are a concern for investors. But the Zacks analyst is encouraged by the fact that Lilly expects to launch 20 new products in a 10 year time-frame ranging from 2014 to 2023 and could launch at least 2 new indications/line extensions on average every year. Moreover, Lilly returned to annual dividend hikes in Dec 2016 and plans to return excess cash through share buybacks. (You can read the full research report on Eli Lily here >>>).
Shares of Buy rated HSBC outperformed the Zacks Foreign Banks industry over the last three months, gaining +7.3% vs -1.7%. The Zacks analyst likes its extensive global network, strong capital position and a solid asset growth. Moreover, continued disposal of unprofitable/non-core operations has enhanced its efficiency, as operating costs remain manageable. Further, the company remains on track to achieve its 2017 cost savings target. However, operating uncertainty in the post-Brexit Europe remains a major cloud on the bank as are recent muted trends in loan demand. (You can read the full research report on HSBC here >>>).
Marriott’s shares have outperformed the Zacks Hotels industry in the year-to-date period (the stock is up +28.9% vs. +3.9% gain for the industry). With the purchase of Starwood, Buy-rated Marriott became the world’s largest hotel company that provides it with increased scale and a robust development pipeline. The Zacks analyst likes Marriott’s rising North American business and large international exposure and thinks they should continue to drive growth. Further, investments in technology for hotel bookings are likely to improve guest experience and thus boost occupancy. Yet, political uncertainties in key international markets and currency headwinds remain causes of concern. (You can read the full research report on Marriott here >>>).
Now See All Our Private Trades While today's Zacks Rank #1 new additions are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for all Zacks trades >>
Sheraz Mian
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Stock Reports for Eli Lily, HSBC, Marriott & Others
Wednesday May 31, 2017
Today's Research Daily features new research reports on 16 major stocks, including Eli Lily (LLY - Free Report) , HSBC (HSBC - Free Report) and Marriott (MAR - Free Report) .You can see all of today’s research reports here >>>
Pharmaceutical stocks have been under pressure since last year on pricing and regulatory concerns and Eli Lily shares have been no different. That said, the stock has done modestly better than the peer group; it is up +5.7% over the last 12 months vs. +1.7% gain for the Zacks Pharma industry and -0.7% decline for the Zacks Medical sector as a whole. Lilly’s recent high-profile pipeline setbacks are a concern for investors. But the Zacks analyst is encouraged by the fact that Lilly expects to launch 20 new products in a 10 year time-frame ranging from 2014 to 2023 and could launch at least 2 new indications/line extensions on average every year. Moreover, Lilly returned to annual dividend hikes in Dec 2016 and plans to return excess cash through share buybacks. (You can read the full research report on Eli Lily here >>>).
Shares of Buy rated HSBC outperformed the Zacks Foreign Banks industry over the last three months, gaining +7.3% vs -1.7%. The Zacks analyst likes its extensive global network, strong capital position and a solid asset growth. Moreover, continued disposal of unprofitable/non-core operations has enhanced its efficiency, as operating costs remain manageable. Further, the company remains on track to achieve its 2017 cost savings target. However, operating uncertainty in the post-Brexit Europe remains a major cloud on the bank as are recent muted trends in loan demand. (You can read the full research report on HSBC here >>>).
Marriott’s shares have outperformed the Zacks Hotels industry in the year-to-date period (the stock is up +28.9% vs. +3.9% gain for the industry). With the purchase of Starwood, Buy-rated Marriott became the world’s largest hotel company that provides it with increased scale and a robust development pipeline. The Zacks analyst likes Marriott’s rising North American business and large international exposure and thinks they should continue to drive growth. Further, investments in technology for hotel bookings are likely to improve guest experience and thus boost occupancy. Yet, political uncertainties in key international markets and currency headwinds remain causes of concern. (You can read the full research report on Marriott here >>>).
Other noteworthy reports we are featuring today include Kinder Morgan (KMI - Free Report) , American Airlines (AAL - Free Report) and Humana (HUM - Free Report) .
Now See All Our Private Trades
While today's Zacks Rank #1 new additions are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for all Zacks trades >>
Sheraz Mian
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>